XOMAO

XOMA Royalty (XOMAO)

XOMA Royalty Corporation

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:XOMAO

1 2 3 4 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/12/19	21 : 30	GlobeNewswire Inc.	XOMA Royalty Declares Quarterly Preferred Stock Dividends	NASDAQ:XOMAO	XOMA Royalty Corporation
2024/12/02	21 : 30	GlobeNewswire Inc.	XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio	NASDAQ:XOMAO	XOMA Royalty Corporation
2024/11/07	21 : 30	GlobeNewswire Inc.	XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities	NASDAQ:XOMAO	XOMA Royalty Corporation
2024/10/22	21 : 00	GlobeNewswire Inc.	XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience	NASDAQ:XOMAO	XOMA Royalty Corporation
2024/09/23	19 : 30	GlobeNewswire Inc.	Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)	NASDAQ:XOMAO	XOMA Royalty Corporation
2024/09/23	18 : 30	GlobeNewswire Inc.	XOMA Royalty Declares Quarterly Preferred Stock Dividends	NASDAQ:XOMAO	XOMA Royalty Corporation
2024/09/04	20 : 30	GlobeNewswire Inc.	XOMA Royalty to Present at Upcoming Investor Conferences in September	NASDAQ:XOMAO	XOMA Royalty Corporation
2024/08/13	20 : 30	GlobeNewswire Inc.	XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities	NASDAQ:XOMAO	XOMA Royalty Corporation
2024/06/20	20 : 30	GlobeNewswire Inc.	XOMA Declares Quarterly Preferred Stock Dividends	NASDAQ:XOMAO	XOMA Royalty Corporation
2024/06/12	20 : 30	GlobeNewswire Inc.	XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher	NASDAQ:XOMAO	XOMA Royalty Corporation
2024/05/14	20 : 30	GlobeNewswire Inc.	XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ	NASDAQ:XOMAO	XOMA Royalty Corporation
2024/05/09	20 : 30	GlobeNewswire Inc.	XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities	NASDAQ:XOMAO	XOMA Royalty Corporation
2024/04/30	20 : 30	GlobeNewswire Inc.	XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%	NASDAQ:XOMAO	XOMA Royalty Corporation
2024/04/25	20 : 30	GlobeNewswire Inc.	XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)	NASDAQ:XOMAO	XOMA Royalty Corporation
2024/04/03	22 : 00	GlobeNewswire Inc.	XOMA Corporation Announces Closing of Tender Offer	NASDAQ:XOMAO	XOMA Royalty Corporation
2024/03/21	20 : 30	GlobeNewswire Inc.	XOMA Declares Quarterly Preferred Stock Dividends	NASDAQ:XOMAO	XOMA Royalty Corporation
2024/03/20	05 : 05	GlobeNewswire Inc.	XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.	NASDAQ:XOMAO	XOMA Royalty Corporation
2024/03/08	21 : 30	GlobeNewswire Inc.	XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value	NASDAQ:XOMAO	XOMA Royalty Corporation
2024/02/28	21 : 30	GlobeNewswire Inc.	XOMA to Present at Upcoming Investor Conferences in March	NASDAQ:XOMAO	XOMA Royalty Corporation
2024/02/16	22 : 00	GlobeNewswire Inc.	XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right	NASDAQ:XOMAO	XOMA Royalty Corporation
2024/01/18	22 : 30	GlobeNewswire Inc.	XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition	NASDAQ:XOMAO	XOMA Royalty Corporation
2024/01/12	06 : 05	GlobeNewswire Inc.	FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx	NASDAQ:XOMAO	XOMA Royalty Corporation
2024/01/08	21 : 30	GlobeNewswire Inc.	XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors	NASDAQ:XOMAO	XOMA Royalty Corporation
2024/01/02	21 : 30	GlobeNewswire Inc.	XOMA Announces Stock Repurchase Program of up to $50 Million	NASDAQ:XOMAO	XOMA Royalty Corporation
2023/12/20	21 : 30	GlobeNewswire Inc.	XOMA Declares Quarterly Preferred Stock Dividends	NASDAQ:XOMAO	XOMA Royalty Corporation
2023/12/19	21 : 30	GlobeNewswire Inc.	XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties	NASDAQ:XOMAO	XOMA Royalty Corporation
2023/11/07	21 : 30	GlobeNewswire Inc.	XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value	NASDAQ:XOMAO	XOMA Royalty Corporation
2023/10/31	20 : 30	GlobeNewswire Inc.	XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)	NASDAQ:XOMAO	XOMA Royalty Corporation
2023/09/25	20 : 30	GlobeNewswire Inc.	XOMA Declares Quarterly Preferred Stock Dividends	NASDAQ:XOMAO	XOMA Royalty Corporation
2023/09/06	20 : 30	GlobeNewswire Inc.	XOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference	NASDAQ:XOMAO	XOMA Royalty Corporation